论文部分内容阅读
目的 观察柯里拉京 (Corilagin)体内、外抗肿瘤活性及其量效关系。 方法 体外药效试验用MTT法 ,体内用小鼠移植性肿瘤及裸鼠移植人肿瘤细胞株观察柯里拉京抑瘤活性及与其他化疗药的协同作用。结果 柯里拉京体外对人卵巢癌细胞 (A2 780 )、鼻咽癌细胞 (KB)、骨肉瘤细胞 (OS 732 )和人结肠癌细胞 (HCT 8)IC50 值分别为 0 .2 5 μg/ml、1.2 μg/ml、7.4 2 μg/ml及 9.0 8μg/ml。体内对小鼠移植性肿瘤及裸鼠移植人肿瘤细胞株也显示出较显著抑制作用。结论 柯里拉京体外对A2 780、KB、OS 732和HCT 8人结肠癌细胞有明显的细胞毒活性 ,体内对小鼠肝癌H2 2 ,裸鼠移植人OS 732、HCT 8也显示出较好的抑制作用。
Objective To observe the antitumor activity of Corilagin in vitro and in vivo and its dose-response relationship. Methods In vitro pharmacodynamic test The antitumor activity of corilagin and the synergistic effect with other chemotherapeutic drugs were observed by MTT method, in vivo transplanted tumor in mice and in nude mice transplanted human tumor cell lines. Results The IC50 values of corilagin in human ovarian cancer cells (A2 780), nasopharyngeal carcinoma cells (KB), osteosarcoma cells (OS 732) and human colon carcinoma cells (HCT 8) were 0.255 μg / ml , 1.2 μg / ml, 7.4 2 μg / ml and 9.0 8 μg / ml. In vivo transplanted tumors in mice and nude mice transplanted human tumor cell lines also showed a more significant inhibitory effect. Conclusion Corilagin in vitro has obvious cytotoxic activity against A2 780, KB, OS 732 and HCT 8 human colon cancer cells, and also shows good cytotoxicity against mouse hepatoma H2 2 and OS 732 and HCT 8 in nude mice in vivo Inhibition.